Talapatra Quoted on Caraco Pharmaceutical v. Novo Nordisk

20 April 2012 FDA Week News

FDA Week

Associate Sunit Talapatra said the Supreme Court’s ruling in Caraco Pharmaceutical v. Novo Nordisk could influence other legal interpretations of the generic drug framework due to the decision’s broad statutory context. However, Talapatra noted that the facts of Caraco are unique to the case and not likely to result in a stratified field of litigation based on use codes.

Related Services

Insights

MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.